Payment overview · 2025
General Payments
$337.42
17 reported records · 7 companies
Healthcare provider profile · identity verified
Nancy Ann Cox, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WRENS, GA · NPI 1811191638
Verified facts
What the public records show
CMS Open Payments records show Nancy Ann Cox, M.D. received $337.42 in general payments during 2025 across 17 reported records.
Novo Nordisk Inc accounted for 43.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $147.67 | 43.8% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $68.10 | 20.2% | 3 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $33.12 | 9.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.50 | 8.2% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $26.80 | 7.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.43 | 5.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.80 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $337.42 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $110.36 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $98.81 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $35.92 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $33.12 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.18 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $27.50 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $26.80 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 179 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
59 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
35 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
53 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
55 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
179 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 492 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 488 | 135 |
| Losartan Potassium | Losartan Potassium | 378 | 114 |
| Fluticasone Propionate | Fluticasone Propionate | 304 | 99 |
| Gabapentin | Gabapentin | 266 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 243 | 72 |
| Lisinopril | Lisinopril | 230 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 219 | 60 |
| Tramadol Hcl | Tramadol Hcl | 215 | 35 |
| Glipizide Er | Glipizide | 212 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 208 | 54 |
| Carvedilol | Carvedilol | 206 | 53 |
| Potassium Chloride | Potassium Chloride | 204 | 53 |
| Simvastatin | Simvastatin | 200 | 57 |
| Metformin Hcl | Metformin Hcl | 195 | 51 |
| Omeprazole | Omeprazole | 195 | 54 |
| Furosemide | Furosemide | 191 | 56 |
| Diclofenac Sodium | Diclofenac Sodium | 187 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 180 | 52 |
| Ozempic | Semaglutide | 179 | 30 |
| Montelukast Sodium | Montelukast Sodium | 175 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 160 | 61 |
| Alendronate Sodium | Alendronate Sodium | 159 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 153 | 39 |
| Meloxicam | Meloxicam | 148 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 38 |
| Alprazolam | Alprazolam | 133 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 127 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 126 | 32 |
| Jardiance | Empagliflozin | 125 | 34 |
| Allopurinol | Allopurinol | 115 | 30 |
| Famotidine | Famotidine | 110 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 94 | 25 |
| Trazodone Hcl | Trazodone Hcl | 90 | 26 |
| Benazepril Hcl | Benazepril Hcl | 80 | 20 |
| Eliquis | Apixaban | 74 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 74 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 73 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 19 |
| Lorazepam | Lorazepam | 68 | suppressed |
| Mirtazapine | Mirtazapine | 66 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 64 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 12 |
| Farxiga | Dapagliflozin Propanediol | 60 | 13 |
| Azithromycin | Azithromycin | 59 | 54 |
| Linzess | Linaclotide | 59 | 24 |
| Atenolol | Atenolol | 58 | 18 |
| Sertraline Hcl | Sertraline Hcl | 58 | 17 |
| Ezetimibe | Ezetimibe | 55 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 16 |
| Clonazepam | Clonazepam | 53 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 53 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 19 |
| Spironolactone | Spironolactone | 48 | 15 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 47 | 14 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Amoxicillin | Amoxicillin | 40 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 13 |
| Glipizide | Glipizide | 40 | 13 |
| Meclizine Hcl | Meclizine Hcl | 40 | 19 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | 11 |
| Ibuprofen | Ibuprofen | 38 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 35 | 35 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Nystatin | Nystatin | 32 | 18 |
| Rybelsus | Semaglutide | 32 | suppressed |
| Fluconazole | Fluconazole | 31 | 23 |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 22 |
| Prednisone | Prednisone | 29 | 13 |
| Colchicine | Colchicine | 28 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | 15 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Indomethacin | Indomethacin | 22 | suppressed |
| Naproxen | Naproxen | 22 | 13 |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 19 |
| Cefdinir | Cefdinir | 20 | 17 |
| Ramipril | Ramipril | 20 | suppressed |
| Sulindac | Sulindac | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 14 |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 17 | 17 |
| Estradiol | Estradiol | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $337.42 · 17 records | Novo Nordisk Inc | AIRSUPRA, Kerendia, NEFFY, Ozempic, Rybelsus, Senza, TRELEGY ELLIPTA, UBRELVY, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error